Year: 2023

Next-gen GaNFast™ technology charges NIO’s first ever phone, with optimized “Vehicle-to-Person” (V2P) integrationNavitas Powers Pioneering NIO Phone with Fast Charging and Seamless EV InteractionNavitas Powers Pioneering NIO Phone with Fast Charging and Seamless EV InteractionTORRANCE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS) announced that NIO, a global, leading, new-energy vehicle maker has released its inaugural smartphone, the NIO Phone with a powerful 66 W fast charger featuring Navitas’ next-generation gallium-nitride (GaN) GaNFast™ power ICs equipped with GaNSense™ technology. This enhancement delivers flagship-level charging efficiency, providing end users with a better vehicle-centric mobile interconnection experience. New GaNFast ICs are replacing...

Pascucci has launched 13 brands and held leadership roles at Diageo, Red Bull, and Pabst Brewing JUPITER, FL, Dec. 07, 2023 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) today announced Rich Pascucci, who has been serving on the Company’s Advisory Board, has joined its Board of Directors. Mr. Pascucci brings a wealth of leadership experience in the beverage industry. He has held leadership and C-suite roles driving portfolio growth for global companies including Diageo, Red Bull, and Pabst Brewing. His responsibilities have included sales, marketing, integration, business insights/category development, national projects, distribution strategy, business planning, public relations and strategic imperatives. Currently, he is the owner of Black Apple Group, LLC, where he specializes in insights, category development, integration,...

Translational data demonstrate synergistic activity of RVU120 and MEK inhibitors in hormone receptor-negative breast cancerKRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) — Ryvu Therapeutics [WSE: RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced promising translational data on RVU120 in combination with MEK inhibitors at the San Antonio Breast Cancer Symposium (SABCS) 2023 being held on December 5–9, 2023, in San Antonio, Texas. “Translational studies showed single agent activity of RVU120 in breast cancer mammosphere models in different subtypes. Importantly, synergistic activity was observed in combination with MEK inhibitors, especially in models with demonstrated EGFR amplification and RAS pathway activation,”...

MIDVALE, Utah, Dec. 07, 2023 (GLOBE NEWSWIRE) — Beyond, Inc., (NYSE: BYON) (“Beyond” or the “Company”), the parent company of online furniture and home furnishings retailer Bed Bath & Beyond, formerly known as Overstock, today announced participation in a virtual fireside chat hosted by Needham & Company on Wednesday, December 13, 2023 at 11 AM ET. Marcus Lemonis, Co-Chair of Beyond Board of Directors, Dave Nielsen, Interim Chief Executive Officer and President, and Adrianne Lee, Chief Financial Officer, will participate in the event. Webcast and Replay InformationTo access the live webcast, please pre-register at this link – BYON Virtual Fireside Chat with Needham. The event is scheduled for one hour. A replay of the event will be available at investors.beyond.com. About BeyondBeyond, Inc. (NYSE:BYON), based in Midvale,...

VANCOUVER, British Columbia, Dec. 07, 2023 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group and TerraZero is pleased to announce that it has initiated a strategy to source partners to integrate and apply Artificial Intelligence (“AI”) and Machine Learning (“ML”) training models to leverage its proprietary data aggregated by BIG over the past 8 years relating to Bitcoin, Ethereum and 14 other blockchains. One of the great advantages that BIGG Digital Assets has is its ownership of both a leading blockchain analytic company, as well as a leading crypto exchange licensed in Canada and many US States. BIG has acquired a tremendous amount of blockchain data, holding 28,922,996,280...

SINGAPORE, Dec. 07, 2023 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited mining and operations updates for November 2023. Linghui Kong, Chief Executive Officer of Bitdeer, commented, “During November, our core business performed steadily and new growth opportunities emerged. Importantly, we became a Preferred Cloud Service Provider in the NVIDIA Partner Network, and announced our plans to launch Bitdeer AI Cloud, a cloud service powered by NVIDIA’s DGX SuperPOD systems. Bitdeer AI Cloud will be among the first cloud services in Asia to be powered by cutting-edge DGX H100 systems. We anticipate that the service will launch in the first quarter of 2024, and we expect expanding...

LAS VEGAS, NV, Dec. 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, is pleased to announce a special Holiday promotion during December, focusing on enhancing general health: the gift of being back at your best. This year, the company proudly introduces special Holiday packs, priced at up to 25% off recommended retail prices. BioAdaptives’ products are all-natural, and scientifically backed, and designed to meet the general wellness needs of the entire adult community, especially Seniors. The growing number of U.S. adults age 65 and older—nearly 56 million as of 2021—represents close to 17% of the total population and a projected 22% by 2040. This sale, which encourages the convenience of online shopping during...

Former Turning Point Brands (NYSE: TPB) General Counsel brings more than three decades of corporate counsel experience focused on nicotine, cannabis, and adjacent consumer categories GRANT-VALKARIA, Fla., Dec. 07, 2023 (GLOBE NEWSWIRE) — Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) (“Kaival Brands,” the “Company,” or “we”), today announced that it has appointed James W. Dobbins as General Counsel effective December 5, 2023. Barry Hopkins, Executive Chairman of Kaival Brands, said, “James Dobbins has extensive experience advising companies on a breadth of legal matters, and importantly, he also has a deep, relevant understanding of industry business operations, including corporate governance, M&A, international sourcing, and compliance matters. Along with an anticipated reduction...

ATHENS, Greece, Dec. 07, 2023 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company” or “Top Ships”) (NASDAQ:TOPS), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today that it has issued 2,930,718 common shares pursuant to an exercise notice for the conversion of 100% of the Series E preferred shares held by a trust for the benefit of family members of the Company’s CEO. Following this issuance, as of the date hereof, the total number of common shares outstanding is 4,626,224, and the CEO together with his family trust owns 3,377,164 common shares, or 73.0% of the outstanding common shares. The common shares issued on conversion of the Series E preferred shares are restricted shares under the Securities Act of 1933, as amended. Along with the shares purchased in the open market by the CEO,...

FREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study. The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II” is a randomized, double-blind, placebo-controlled study involving a total...